Central Drugs Standard Control Organization (CDSCO) expert panel has given approval COVID-19 vaccine Sputnik-V emergency use. Though the Drugs Controller General of India (DGCI) will consider it and make a final decision. If Sputnik V gets approval, will be 3rd COVID-19 vaccine be accessible to use in India.
Russia has developed and worked to prepare the Sputnik V vaccine. Russian Direct Investment Fund has collaborated with Dr. Reddy's Laboratories to perform clinical research and trials n the vaccines and their allocation rights in India. The vaccine has authenticated 91.6% efficiency throughout its 3rd phase trials.
Presently, the COVISHIELD of AstraZeneca and COVAXIN of Bharat Biotech vaccines have been approved to use and under the Government of India's supervision. The government of India has approved Emergency Use Authorization for both vaccines. Vaccine interim approval is Emergency Use Authorization.
An organization looking for Emergency Use Authorization mandatorily perform local trials to authenticate that vaccines are safe and productive on Indian citizens.
Post every clinical trial; the vaccine is improved by abolishing its side effect and possible harms. However, in the emergency Use Authorization, there is no time for these thorough trials.
However, the Emergency Use Authorized vaccines vaccine may have possible side effects. In case of such side effects, the vaccine manufacturer entity or partner should inform the people about the potential side effects.
Other drugs that have been sanctioned for Emergency Use Authorization in India are Itolizumab, Favipiravir, and Remdesivir.